1-3 of 3
Olga Vasiljeva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2020–2029.
https://doi.org/10.1158/1078-0432.CCR-21-3656
Published: 13 May 2022
View article titled, Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Open the PDF for Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Marjolijn N. Lub-de Hooge, Iris C. Kok, Adrienne H. Brouwers, Sjoerd G. Elias, Margaret T.L. Nguyen, Hong Lu, Jourik A. Gietema, Mathilde Jalving, Derk J.A. de Groot, Olga Vasiljeva, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5325–5333.
https://doi.org/10.1158/1078-0432.CCR-21-0453
Published: 01 October 2021
View article titled, First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Open the PDF for First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody in another window
Includes: Supplementary data
Journal Articles

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howng, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, Martin Pool
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3999–4009.
https://doi.org/10.1158/1078-0432.CCR-19-3137
Published: 03 August 2020
View article titled, Probody Therapeutic Design of <sup>89</sup>Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Open the PDF for Probody Therapeutic Design of <sup>89</sup>Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue in another window
Includes: Supplementary data